Ketamine dose may cut suicidal thinking in depressed patients

Image
IANS New York
Last Updated : May 11 2016 | 7:23 PM IST

Low doses of a general anaesthetic drug is likely to reduce suicidal thoughts in patients with treatment-resistant depression, finds a new study.

The findings showed that repeatedly infusing low doses of ketamine in depressed patients with recurrent suicidal thoughts might help them in recovering rapidly.

"Our finding that low doses of ketamine, when added on to current antidepressant medications quickly decreased suicidal thinking in depressed patients, is critically important because we don't have many safe, effective and easily available treatments for these patients," said Dawn Ionescu, lead researcher from Massachusetts General Hospital (MGH) in the US.

Having suicidal thoughts increases the risk that patients will attempt suicide. However, the risk of suicide attempts is 20 times higher in patients with depression than the general population.

The study, published online in the Journal of Clinical Psychiatry, was designed not only to examine the antidepressant and anti-suicidal effects of repeated low-dose ketamine infusions, but also to examine the safety of increased ketamine dosage.

The team enrolled 14 patients with moderate to severe treatment-resistant depression who had suicidal thoughts for three months or longer and they received two weekly ketamine infusions over a three-week period.

The initial dosage administered was 0.5 mg/kg over a 45-minute period -- about five times less than a typical anaesthetic dose -- and after the first three doses, it was increased to 0.75 mg/kg.

The participants were assessed on measures of suicidal thinking, in which patients were directly asked to rank whether they had specific suicide-related thoughts, their frequency and intensity.

The results showed that most of them experienced a decrease in suicidal thinking, and seven achieved complete remission of suicidal thoughts at the end of the treatment period.

"The study that aim to understand the mechanism by which ketamine and its metabolites work for people with suicidal thinking and depression may help us discover areas of the brain to target with new, even better therapeutic drugs," Ionescu concluded.

--IANS

rt/bim/dg

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 11 2016 | 7:14 PM IST

Next Story